Full-Time
Senior Analyst
CRM Operations
Vertex Pharmaceuticals
5,001-10,000 employees
Develops therapies for serious genetic diseases
Compensation Overview
$104k - $156k/yr
Company Does Not Provide H1B Sponsorship
Boston, MA, USA
Hybrid
Hybrid work allows up to two remote days per week, or five days per week on-site.
Bachelor's
 Data & Analytics (1) |
|---|
Get referred to Vertex Pharmaceuticals
See people who can refer or advise you
- A Bachelor's degree in Business, IT, or a related field.
- Strong organizational, communication, and analytical skills.
- Experience with customer relationship management systems, preferably Veeva CRM, in a regulated environment.
- Familiarity with agile methodologies and tools.
- Interest in artificial intelligence technologies and their application in customer relationship management and master data management processes.
- Proficiency in artificial intelligence tools such as Copilot Studio, GitHub Copilot, or similar platforms.
- Knowledge of software development life cycle and information technology service management processes with artificial intelligence integration.
- Experience with backlog management and agile delivery tools.
- Gather, analyze, and document business requirements, user stories, process maps, and acceptance criteria for Veeva CRM enhancements and artificial intelligence-driven projects.
- Define and deliver artificial intelligence solutions within software development life cycle and information technology service management processes to improve scalability and operational efficiency.
- Support the translation of commercial business needs into functional and technical requirements, incorporating artificial intelligence capabilities for extended development tools such as Copilot Studio and GitHub Copilot.
- Assist with backlog management and prioritization, ensuring alignment with artificial intelligence readiness and process improvement goals.
- Conduct impact assessments for system changes, enhancements, and platform releases across markets, with a focus on artificial intelligence integration.
- Support user acceptance testing, defect tracking, and validation of artificial intelligence-enhanced system functionality against business requirements.
- Contribute to platform standard operating procedures and capability documentation to support artificial intelligence adoption and DevOps best practices.
- Facilitate agile ceremonies for the delivery team, including daily stand-ups, sprint planning, backlog refinement, sprint reviews, and retrospectives.
- Help the team stay focused on sprint goals, timelines, and delivery commitments, incorporating artificial intelligence-driven insights to optimize workflows.
- Track actions, risks, dependencies, and blockers, escalating where appropriate to ensure seamless artificial intelligence implementation.
- Ensure user stories are clearly defined, prioritized, and ready for development, with a focus on artificial intelligence-driven enhancements.
- Support coordination across global business, information technology, and vendor teams to enable artificial intelligence readiness and functional specialization.
- Collaborate with managed service providers to ensure operational efficiency and alignment with service-level agreements.
- Drive adherence to DevOps standards and best practices to ensure robust and scalable CRM operations.
- Identify opportunities for process improvement and data management to support artificial intelligence readiness and streamline demand management and governance.
- Hands-on experience with artificial intelligence implementation in CRM systems.
- Expertise in process improvement and data management to support artificial intelligence readiness.
- Functional business analyst expertise in CRM to support evolving portfolios.
- Agile, DevOps, or ITIL certification.
Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1989
Get referred to Vertex Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Vertex raised 2026 revenue guidance to $13.1-$13.2 billion after Q2 growth.
- Povetacicept has a November 30, 2026 PDUFA date, opening nephrology revenue.
- JOURNAVX hit $50 million in Q2 2026, while CASGEVY grew 151% year over year.
What critics are saying
- Sionna axed SION-719 on August 10, 2026, but CF competition keeps advancing.
- Zimislecel faced a voluntary manufacturing pause in 2026, exposing cell-therapy execution risk.
- Crinetics adds $8.8 billion integration risk; a failed close leaves Vertex overdependent on CF.
What makes Vertex Pharmaceuticals unique
- Vertex still owns CFTR modulators; Q2 2026 CF revenue reached $3.2 billion.
- Vertex broadened beyond CF with CASGEVY, JOURNAVX, and Crinetics, announced July 2026.
- Vertex moves fast: CASGEVY pediatric FDA approval arrived 53 days after filing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 8%1 year growth
↑ 8%2 year growth
↑ 8%Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]
Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.
Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.
Sionna Therapeutics is challenging Vertex Pharmaceuticals' dominance in the cystic fibrosis (CF) drug market. Vertex, valued at nearly $123 billion, generated $3.2 billion in CF-related sales in Q2, representing most of its $3.33 billion total revenue. Sionna, worth $2.2 billion, claims its approach could restore normal function to the CFTR protein, which causes CF when misfolded. Vertex's current treatments improve the protein's shape and function but don't restore normal function for most patients. Vertex generates over $12 billion annually from CF treatments. However, several companies, including AbbVie, have previously attempted to challenge Vertex's market position without success. Vertex has maintained its position since receiving its first CF drug approval in 2012.